Home › Free Stock Grades › IBRX
ImmunityBio, Inc. (IBRX) Stock Grade
IBRX · Healthcare
C
Market Cap
$8.9B
P/E Ratio
—
Revenue Growth (YoY)
+668.3%
Net Margin
-310.2%
Return on Equity
70.3%
Dividend Yield
None
About ImmunityBio, Inc.'s fundamentals
ImmunityBio is a biotechnology company with a $8.9 billion market capitalization that reported exceptional revenue growth of 668.3% year-over-year, indicating rapidly expanding commercial activity. However, the company is currently unprofitable with a negative net margin of -310.2% and reported a net loss in its latest annual statement, meaning expenses significantly outpace revenues. The company does not pay a dividend and lacks a traditional P/E ratio due to its loss-making status, which is common among early-stage biotech firms investing heavily in research and development.